African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy

Jeffrey A. Canter, Gregory K. Robbins, Doug Selph, David B. Clifford, Asha R. Kallianpur, Robert Shafer, Shawn Levy, Deborah G. Murdock, Marylyn D. Ritchie, David W. Haas, Todd Hulgan

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


Susceptibility to peripheral neuropathy during antiretroviral therapy with nucleoside reverse-transcriptase inhibitors was previously associated with a European mitochondrial DNA (mtDNA) haplogroup among non-Hispanic white persons. To determine whether nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy was related to mtDNA variation in non-Hispanic black persons, we sequenced mtDNA of participants from AIDS Clinical Trials Group study 384. Of 156 non-Hispanic black persons with genomic data, 51 (33%) developed peripheral neuropathy. In a multivariate model, African mtDNA subhaplogroup L1c was an independent predictor of peripheral neuropathy (odds ratio, 3.7 [95% confidence interval, 1.1-12.0]). An African mtDNA subhaplogroup is for the first time implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated toxicity.

Original languageEnglish (US)
Pages (from-to)1703-1707
Number of pages5
JournalJournal of Infectious Diseases
Issue number11
StatePublished - Jun 1 2010

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy'. Together they form a unique fingerprint.

Cite this